From the blog

Efficacy and Safety of PIPAC/PITAC in Gastric,Ovarian, Colorectal Cancer and Mesothelioma With Pleural Carcinomatosis. (PIPAC/PITAC)

Published: May 4, 2016

Primary Outcome Measures

    • Clinical Benefit Rate (CBR) according to RECIST criteria after three cycles of PIPAC/PITAC [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures

      • Peritoneal carcinomatosis index (PCI) [ Time Frame: 2 years ] [ Designated as safety issue: No]
      • Histological tumor regression/progression [ Time Frame: 2 years ] [ Designated as safety issue: No]
      • Time until tumor progression [ Time Frame: 2 years ] [ Designated as safety issue: No]
      • Ascites/pleural affusion volume [ Time Frame: 2 years ] [ Designated as safety issue: No]
      • Degree of tumor cell apoptosis [ Time Frame: 2 years ] [ Designated as safety issue: No]
      • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Detailed Description:
Outcome data for 200 patients (50 patients each of with gastric, ovarian, colorectal, or pleural cancer/mesothelioma with peritoneal/pleural carcinomatosis) undergoing pressurized intraperitoneal/intrathoracal aerosol chemotherapy (PIPAC/PITAC) with cisplatin and doxorubicin or oxaliplatin.

The indication depends on the tumor entity and spread, the previous chemotherapeutic therapy and the patient’s condition. If these are matched and the indication for PIPAC/PITAC therapy is provided by a multidisciplinary Tumorboard, the patient will be offered to undergo PIPAC/PITAC therapy. Despite PIPAC/PITAC therapy entails an off label use of the chemotherapeutic agents, health insurance covers the treatment for carefully selected patients after special approval. With this observational study, the Klinik Hirslanden aims at monitoring treated patients and to evaluate the safety and efficacy properties of PIPAC/PITAC treatment.

Eligibility

Study Population

Confirmed diagnosis of gastric, ovarian, colorectal or pleural (mesothelioma) cancer and peritoneal/pleural carcinomatosis with disease progression after at least one line of previous intravenous chemotherapy. Depending on these first results, the data recording will be continued (open end).

Criteria

Inclusion Criteria
Age>18 years Provided indication for PIPAC/PITAC Informed consent
Exclusion Criteria
Patient unable to communicate Refusal of informed consent
Contact Us
CONTACT INFORMATION
DIAGNOSIS
Have you received a diagnosis? *
reCAPTCHA